In this essay, Michel Goldman discusses the lessons from the pandemic that should influence medicine as a whole. After tracing the evolution of anti-infective strategies, he explains how the study of rare diseases […]

A key paper on financing biomedical innovation: link here.

Review of literature on financial intermediation in the process by which new medical therapeutics are financed, developed, and delivered.

DULBEA, Solidaris & CIRIEC – 16^th of November – Dupréel Room (ULB Solbosch)

In collaboration with Solidaris and CIRIEC, the DULBEA is organising an international conference on the 16^th of November 2022 in the Dupréel room at the […]

Registrations for the 8th edition of the Interdisciplinary Program is now open.

Full program will be available soon.

Please find all the information on our dedicated page: here

Le Pr Michel Goldman (Professeur émérite d’immunologie et président de l’Institut interdisciplinaire pour l’innovation en santé à l’ULB) vient de publier un article consacré au Covid long dans Frontiers of Medicine. Il en commente les […]

Quel intérêt pour le dosage des anticorps anti-Covid ? Ci-dessous les réponses de Michel Goldman à Laurence Dardenne dans La Libre.

1. Comment mesure-t-on le taux d’anticorps?

Le test sérologique Covid-19 consiste en […]